Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health Rituximab Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 5328-D

    Medicare Part B Step Therapy Rituximab Products

    Customize your policy alerts

    Sign up for zing_health Policy 5328-D alerts

    Get alerted when Policy 5328-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs preferred-product sequencing and prior authorization exceptions for Zing Health Medicare Part B members requesting rituximab products. Non-preferred products may be covered when specified prior-use or intolerance criteria are met, in addition to applicable Medicare coverage and utilization management requirements.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Rituximab Products
    Policy CodePolicy 5328-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for a non-preferred rituximab product and document the clinical circumstances supporting an exception to the preferred products.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Medicare Part BApplicable benefit and program
    2Preferred rituximab products
    3Non-preferred rituximab products
    365 daysPrior-use lookback
    2
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Rituximab Products
    Policy CodePolicy 5328-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization for a non-preferred rituximab product and document the clinical circumstances supporting an exception to the preferred products.
    SourceLink
    On This Page
    Non-Preferred Product Coverage CriteriaInitial Coverage for Non-Preferred ProductsPreferred Product SequencingPrior Authorization and DocumentationKey DefinitionsPreferred Rituximab Products

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Preferred products for intolerance exception

    Non-Preferred Product Coverage Criteria

    Non-preferred Product Coverage Criteria

    Coverage for a non-preferred product is provided when ANY of the following criteria is met:

    ANY of the following

    • Member has received treatment with the non-preferred product in the past 365 days.within the past 365 days
    • Member has had a documented intolerable adverse event to both of the preferred products, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., a known adverse reaction for both the reference product and biosimilar products).

      Documentation must establish an intolerable adverse event to both preferred products and confirm that it was not an expected adverse event attributed to the active ingredient.

    Initial Coverage for Non-Preferred Products

    Non-preferred Product Initial Coverage

    Coverage for a non-preferred product is provided when either of the following criteria is met.

    At least one of the following

    • Qualifying prior treatment: The member has received treatment with the requested non-preferred product within the past 365 days.within the past 365 days
    • Qualifying intolerance: The member has had a documented intolerable adverse event to both preferred products, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.both preferred products

      This includes a known adverse reaction to both the reference product and biosimilar products.

    Preferred Product Sequencing

    StepPreferred productsNon-preferred productsCoverage requirement
    1Ruxience (rituximab-pvvr); Truxima (rituximab-abbs)Riabni (rituximab-arrx); Rituxan (rituximab); Rituxan Hycela (rituximab and hyaluronidase human)Covered when the member received the requested non-preferred product within the past 365 days, or had a documented intolerable adverse event to both preferred products that was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for requests for non-preferred rituximab products. The review evaluates clinical circumstances that exclude use of the preferred product, including qualifying prior use or documented intolerance, in addition to applicable NCD, LCD, and Medicare Part B utilization-management requirements.

    • Applies to all members requesting treatment with a non-preferred product.
    • Coverage review may establish a clinical exception based on the member’s clinical circumstances.
    Step Therapy

    Follow Preferred-Product Sequencing

    Use the preferred rituximab products before requesting a non-preferred product. A non-preferred product may be covered only when a qualifying prior-use or intolerance exception is established.

    • Step therapy applies in addition to applicable NCD, LCD, and Medicare Part B utilization-management programs.
    • The program applies to the rituximab products specified in the policy.

    Key Definitions

    Intolerable adverse event
    DefinitionAn adverse event that is not an expected adverse event attributed to the active ingredient as described in the prescribing information.
    Documentation requirementThe adverse event must be documented for both preferred products.
    Product scopeThe requirement applies to both the reference product and biosimilar products.

    Preferred Rituximab Products

    Billing Rule

    Preferred rituximab product: Ruxience

    Ruxience (rituximab-pvvr) is a preferred rituximab product. Use it in accordance with the plan’s preferred-product sequencing requirements unless a qualifying exception for a non-preferred product is established.

    Billing Rule

    Preferred rituximab product: Truxima

    Truxima (rituximab-abbs) is a preferred rituximab product. Use it in accordance with the plan’s preferred-product sequencing requirements unless a qualifying exception for a non-preferred product is established.

    Documentation Required

    Document the Exception

    Document the evidence supporting an exception for the non-preferred product. The record must establish either treatment with the non-preferred product within the past 365 days or an intolerable adverse event to both preferred products that was not an expected active-ingredient-related adverse event described in the prescribing information.

    • For prior use: document receipt of the non-preferred product within the previous 365 days.
    • For intolerance: document an intolerable adverse event to both preferred products.
    • The adverse event must not be an expected adverse event attributed to the active ingredient, including a known adverse reaction to both the reference product and biosimilar products.
    Denial Risk

    Exception Criteria Not Met

    A non-preferred product does not meet the step-therapy exception when neither qualifying prior use nor the required documented intolerance is established. Requests without one of these exceptions may be denied.

    • No documented treatment with the non-preferred product in the past 365 days.
    • No documented intolerable adverse event to both preferred products that meets the policy requirements.